These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20332044)

  • 1. Reaping the early harvest of the genomics revolution.
    Chung RT
    Gastroenterology; 2010 May; 138(5):1653-4. PubMed ID: 20332044
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive.
    Wapner J
    Science; 2010 Oct; 330(6004):579. PubMed ID: 21030622
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C virus infection and genetic susceptibility to therapy.
    Sibbing B; Nattermann J
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):397-406. PubMed ID: 22187706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.
    Cariani E; Villa E; Rota C; Critelli R; Trenti T
    Clin Chem Lab Med; 2011 Aug; 49(8):1247-1256. PubMed ID: 21612542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes?
    McCaughan GW; Shackel NA; Bowen DG
    Liver Transpl; 2011 Mar; 17(3):219-21. PubMed ID: 21384503
    [No Abstract]   [Full Text] [Related]  

  • 6. Innate and adaptive genetic pathways in HCV infection.
    Buchanan R; Hydes T; Khakoo SI
    Tissue Antigens; 2015 Apr; 85(4):231-40. PubMed ID: 25708172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.
    Venegas M; Brahm J; Villanueva RA
    Ann Hepatol; 2012; 11(6):827-37. PubMed ID: 23109445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of hepatocellular carcinoma and response to interferon therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC.
    Toyoda H; Kumada T
    Liver Int; 2012 Jul; 32(6):1029-31. PubMed ID: 22314231
    [No Abstract]   [Full Text] [Related]  

  • 9. IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
    Lange CM; Zeuzem S
    J Hepatol; 2011 Sep; 55(3):692-701. PubMed ID: 21440591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alfa, interferon-lambda and hepatitis C.
    O'Brien TR
    Nat Genet; 2009 Oct; 41(10):1048-50. PubMed ID: 19749756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic factors and hepatitis C virus infection.
    Thompson AJ
    Gastroenterology; 2012 May; 142(6):1335-9. PubMed ID: 22537440
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.
    Eurich D; Boas-Knoop S; Ruehl M; Schulz M; Carrillo ED; Berg T; Neuhaus R; Neuhaus P; Neumann UP; Bahra M
    Liver Transpl; 2011 Mar; 17(3):289-98. PubMed ID: 21384511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomics: playing the odds.
    Maxmen A
    Nature; 2011 Jun; 474(7350):S9-10. PubMed ID: 21666735
    [No Abstract]   [Full Text] [Related]  

  • 16. Host genomics and HCV personalized medicine.
    Slev P
    Ann Clin Lab Sci; 2012; 42(4):363-9. PubMed ID: 23090731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection.
    Holmes JA; Desmond PV; Thompson AJ
    Clin Liver Dis; 2011 Aug; 15(3):497-513. PubMed ID: 21867933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes.
    Lagging M
    Pharmacogenomics; 2012 Jun; 13(8):847-9. PubMed ID: 22676186
    [No Abstract]   [Full Text] [Related]  

  • 19. [IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C].
    Labie D; Gilgenkrantz H
    Med Sci (Paris); 2010 Mar; 26(3):225-6. PubMed ID: 20346265
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
    Thomas DL; Thio CL; Martin MP; Qi Y; Ge D; O'Huigin C; Kidd J; Kidd K; Khakoo SI; Alexander G; Goedert JJ; Kirk GD; Donfield SM; Rosen HR; Tobler LH; Busch MP; McHutchison JG; Goldstein DB; Carrington M
    Nature; 2009 Oct; 461(7265):798-801. PubMed ID: 19759533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.